Switching from oral antipsychotic to long-acting injectable

The decision to switch from a daily oral antipsychotic to a long-acting injectable is, for many people, the single most useful change they make in years. Hospitalisation rates fall. The daily decision to take a pill — a decision that anosognosia, side effects, or simple human forgetfulness can derail — disappears. But the transition itself takes planning. Each LAI has its own conversion strategy, oral overlap requirement, and initiation steps. This guide is about the practical mechanics.

Step 1: Confirm tolerance on the oral form

For most LAIs, FDA labelling and clinical practice require that the patient has tolerated the oral form of the same medication first. This is to confirm that the patient is not allergic, that side effects are manageable, and that the medication is a reasonable fit. The duration varies — sometimes a week, sometimes longer — and is decided by the prescriber.

Specific examples:

• Aripiprazole LAIs (Aristada, Abilify Maintena) — typically at least two weeks of oral aripiprazole tolerated
• Risperidone LAIs (Risperdal Consta, Uzedy, Perseris) — typically several days to a week of oral risperidone
• Paliperidone LAIs (Invega Sustenna, Erzofri, Invega Trinza, Hafyera) — oral paliperidone or oral risperidone tolerance is usually sufficient
• Olanzapine LAI (Zyprexa Relprevv) — prior tolerance of oral olanzapine
• Haloperidol decanoate — prior stable response to oral haloperidol
• Fluphenazine decanoate — prior stable response to oral fluphenazine

Step 2: Calculate the dose

Each LAI has a conversion approach that maps the oral dose to the injectable dose. A few examples:

• Haloperidol decanoate — monthly depot dose typically 10 to 20 times the daily oral dose, capped at 100 mg per single injection
• Risperdal Consta — typically 25 mg every 2 weeks for patients on 2 mg/day oral, 37.5 mg for 3 mg/day, 50 mg for 4 mg/day or higher
• Invega Sustenna — initiation with 234 mg on day 1 and 156 mg on day 8, then a maintenance dose chosen based on the prior oral paliperidone or risperidone dose
• Aristada — strength chosen based on prior oral aripiprazole; 441 mg, 662 mg, 882 mg, or 1064 mg with corresponding intervals

Conversion tables are guidance — the final dose decision belongs to the prescriber, who will adjust based on age, body size, tolerability, and clinical response.

Step 3: Choose the oral overlap or loading strategy

This is the step that varies most between LAIs.

LAIs that require oral overlap

• Risperdal Consta — three weeks of continued oral risperidone after the first injection while depot levels build up
• Aristada (without Aristada Initio) — typically 21 days of oral aripiprazole
• Abilify Maintena — 14 days of oral aripiprazole
• Haloperidol decanoate and fluphenazine decanoate — oral form often continued and tapered over the first weeks

LAIs that use a loading-dose strategy instead of oral overlap

• Invega Sustenna — two injections in the first week (day 1 and day 8) eliminate the need for oral overlap

LAIs that require neither oral overlap nor a separate loading injection

• Erzofri — single starting injection produces therapeutic levels
• Uzedy — single subcutaneous injection produces therapeutic levels
• Aristada Initio + first Aristada maintenance dose — replaces the 21 days of oral aripiprazole
• Perseris — single subcutaneous injection produces therapeutic levels
• Zyprexa Relprevv — generally does not require oral olanzapine overlap, though three hours of post-injection observation is required

Step 4: Plan the first appointment

Practical considerations:

• Where will the injection be given? — clinic, community mental health centre, primary care office; some areas now offer pharmacy-administered LAIs
• Who will give it? — nurse, physician, nurse practitioner
• Site of injection — deltoid is generally smaller volume; gluteal is larger volume and used for higher-dose injections
• Observation — three hours required for Zyprexa Relprevv; typically not required for other LAIs
• How will the next appointment be scheduled? — most clinics schedule the next injection on the day of the current one

Step 5: Manage the transition emotionally

Switching to an LAI can feel like loss of control for some patients. The pill is something the patient gives themselves; the injection is something done to them. Common feelings:

• Anxiety about the injection itself
• Concern about being "stuck" with the medication for weeks
• Worry about side effects that cannot be quickly stopped

These concerns are reasonable and worth discussing openly with the prescriber. Useful framing: most LAIs have an oral form that has been tolerated for weeks before the switch, so the medication itself is not new — only the route. And while the depot lasts weeks, side effects can usually be managed with adjunctive medications, dose reduction at the next interval, or ultimately a switch to a different LAI.

Step 6: Track the response

The first three months on an LAI are the most informative. Worth tracking:

• Mood, sleep, anxiety
• Side effects — particularly akathisia, sedation, EPS
• Injection-site reactions
• Cravings to discontinue (these are common and worth talking through rather than acting on)
• Changes in psychotic symptoms

Apps like Frida and simple paper journals both work for this. Bring the data to each injection appointment.

What if it does not work?

Switching off an LAI takes time because depot levels persist for weeks. If a patient and prescriber decide the LAI is not working, options include:

• Adjusting the dose or interval at the next injection
• Adding adjunctive medications for specific side effects
• Switching to a different LAI — timing of the new product is planned around the depot half-life of the previous one
• Returning to oral medication, sometimes with a new adherence strategy

Helpful questions to bring to your prescriber

• Why this particular LAI rather than the others?
• What is the conversion plan from my oral dose?
• Do I need oral overlap, a loading dose, or neither?
• Where will the injection be given, and how often?
• What's the plan for missed appointments?
• If this LAI does not work, what's our next move?

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed sources. Always consult your prescribing clinician before starting, stopping, or changing any medication.